Lupus patient decisions about clinical trial participation: a qualitative evaluation of perceptions, facilitators and barriers
Open Access
- 15 March 2020
- journal article
- research article
- Published by BMJ in Lupus Science & Medicine®
- Vol. 7 (1), e000360
- https://doi.org/10.1136/lupus-2019-000360
Abstract
Objective Although SLE disproportionately affects minority racial groups, they are significantly under-represented in clinical trials in the USA. This may lead to misleading conclusions in race-based subgroup analyses. We conducted focus groups to evaluate the perceptions of diverse patients with lupus about clinical trial participation. Methods A qualitative research design employed three 90 min focus groups led by a trained moderator and guided by the Theory of Planned Behaviour. Open-ended questions about trial participation included advantages and disadvantages (behavioural beliefs), approving and disapproving significant others (normative beliefs), and participation enhancers and barriers (control beliefs). Discussions were recorded, transcribed and analysed to identify emerging themes. Results Patients with SLE (n=23) aged 21–72, with increased proportion of minority groups (65%), participated. Reported advantages of trial participation included altruism and personal benefit. Disadvantages included uncertainties, disappointment, information burden, and life–health balance. Although some patients had discussed research participation with approving or disapproving family or friends, self-approval superseded external approval. Barriers included logistics and time, and facilitators included flexibility in scheduling, advance notice of studies, streamlined forms, and hope for SLE improvement. Conclusions Knowledge about potential benefits of clinical trial participation was high. Minority patients demonstrated confidence in making their own informed decisions, but major barriers for all participants included burdensome forms, travel, childcare, and work. These suggest a major impact on minority and all recruitment from behavioural and control aspects, which should be considered in the logistics of trial design. This does not minimise the potential importance of improved access and education about clinical research.Keywords
Funding Information
- U.S. Department of Health and Human Services: Office of Minority Health (CPI-MP-17-002-1 2017 National Lupus Outreach)
This publication has 38 references indexed in Scilit:
- A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosusArthritis & Rheumatism, 2011
- Influence of race/ethnicity on response to lupus nephritis treatment: the ALMS studyRheumatology, 2009
- A phase II, randomized, double‐blind, placebo‐controlled, dose‐ranging study of belimumab in patients with active systemic lupus erythematosusArthritis Care & Research, 2009
- Long‐term medical costs and resource utilization in systemic lupus erythematosus and lupus nephritis: A five‐year analysis of a large medicaid populationArthritis Care & Research, 2009
- Mycophenolate Mofetil versus Cyclophosphamide for Induction Treatment of Lupus NephritisJournal of the American Society of Nephrology, 2009
- Reducing Cancer Disparities for Minorities: A Multidisciplinary Research Agenda to Improve Patient Access to Health Systems, Clinical Trials, and Effective Cancer TherapyJournal of Clinical Oncology, 2006
- Systemic lupus erythematosus in three ethnic groups. XII. Risk factors for lupus nephritis after diagnosisLupus, 2002
- Minority Recruitment In Clinical Trials: A Conference at Tuskegee, Researchers and the CommunityAnnals of Epidemiology, 2000
- Updating the American college of rheumatology revised criteria for the classification of systemic lupus erythematosusArthritis & Rheumatism, 1997
- The theory of planned behaviorOrganizational Behavior and Human Decision Processes, 1991